A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Status:
Unknown status
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within
the biliary tract, characterized by innate chemoresistance and abysmal prognosis. PD-1
blockade has been developed to a new class of cancer immunotherapy that could restore an
adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer
immune responses. Manganese has been confirmed to activate antigen-presenting cells and
function as mucosal immunoadjuvants in pre-clinical studies. This open-label, phase I/II
study is designed to assess the safety and efficacy of Manganese primed combined therapy of
anti-PD-1 antibody and gemcitabine/cisplatin chemotherapy.